Ionis Pharmaceuticals (IONS) Current Deferred Revenue (2009 - 2026)

Ionis Pharmaceuticals has reported Current Deferred Revenue for 18 years, with the latest figure at $69.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue rose 1509.28% year-over-year to $69.2 million; the trailing twelve-month figure through Mar 2026 stood at $69.2 million (up 1509.28% YoY), and the FY2025 full-year result was $73.8 million, down 6.62% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $69.2 million, down from $73.8 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $204.8 million in Q3 2023, with the low at $4.3 million in Q1 2025.
• Average Current Deferred Revenue over 5 years is $94.1 million, with a median of $91.4 million recorded in 2022.
• Year-over-year, Current Deferred Revenue slumped 96.7% in 2025 and jumped 1509.28% in 2026.
• Tracing IONS's Current Deferred Revenue over 5 years: stood at $90.6 million in 2022, then jumped by 66.85% to $151.1 million in 2023, then tumbled by 47.73% to $79.0 million in 2024, then declined by 6.62% to $73.8 million in 2025, then declined by 6.18% to $69.2 million in 2026.
• The last three Current Deferred Revenue figures came in at $69.2 million (Q1 2026), $73.8 million (Q4 2025), and $77.0 million (Q3 2025), per Business Quant data.

Peer Comparison